2023 World Conference on Lung Cancer (Posters)-EP12.01. First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases

EP12.01. First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases - PDF(Abstract)

Back to course

Pdf Summary

This document is a case report presented at the World Conference on Lung Cancer in 2023. The report discusses the treatment of two patients with non-small cell lung cancer (NSCLC) who had primary EGFR T790M mutation. The aim of the report is to evaluate the effectiveness and safety of aumolertinib monotherapy as a first-line treatment for these patients.<br /><br />The first patient, a 64-year-old female, presented with symptoms such as dry cough, chest tightness, and suffocation. Imaging tests revealed lung cancer with lymph node and bone metastasis. Genetic testing showed two separate EGFR mutations: L858R in exon 21 and primary T790M in exon 20. Due to the ineffectiveness of first-generation EGFR-TKI, the patient started taking aumolertinib 110mg once daily. Two months later, a partial response was observed with a reduction in tumor markers. After 22 months of aumolertinib treatment, the disease progressed, and the patient received chemotherapy as a second-line treatment.<br /><br />The second patient, a 61-year-old female, presented with a dry cough. Imaging tests revealed lung nodules with lymph node and bone metastasis. Genetic testing showed the same mutations as the first patient. The patient was also treated with aumolertinib 110mg per day and achieved a partial response after 8 months. At the last follow-up, the patient had been on aumolertinib treatment for 24 months with sustained disease control and no significant adverse events.<br /><br />The report concludes that aumolertinib monotherapy showed a durable disease control and a satisfying safety profile in these two cases. It suggests that aumolertinib can be considered as a treatment option for NSCLC patients with primary EGFR T790M mutation. This report provides valuable insights into the use of targeted therapy in NSCLC patients with specific genetic mutations.

Asset Subtitle

Li Zang

Meta Tag

Speaker Li Zang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

World Conference on Lung Cancer

case report

NSCLC

EGFR T790M mutation

aumolertinib monotherapy

partial response

disease progression

genetic testing

sustained disease control

targeted therapy